Skip to main content
Caplight Logo









Suzhou HepaThera Biotech Co., Ltd.

Suzhou HepaThera Biotech Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://hepathera.com/

Last Round

Pre Seed

Feb 1, 2023

Total Funding Raised

$14.7M

Company Overview

Suzhou HepaThera Biotech Co., Ltd. is a biotechnology company that develops innovative therapies for the treatment of liver diseases, including hepatitis B and D.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalliver diseasedrug discoverymetabolic disordersdrug developmentclinical trialsR&Dsmall moleculebiotechhepatologydrug licensingtherapeutic assetsclinical-stagepharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Suzhou HepaThera Biotech Co., Ltd. Comparables

Compare Suzhou HepaThera Biotech Co., Ltd. with similar companies based on industry and business-model similarity.

Suzhou HepaThera Biotech Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shanghai Hepu Pharmaceutical Co., Ltd.
82%
Ascletis Pharma Inc.
76%
HighTide Therapeutics Inc
73%

Suzhou HepaThera Biotech Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedFeb 1, 2023
SeedNov 1, 2021

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 1, 2023

    $15M raised in Pre Seed round.

Suzhou HepaThera Biotech Co., Ltd. Filings

Explore SEC and related filing metadata, where available.

Suzhou HepaThera Biotech Co., Ltd. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Suzhou HepaThera Biotech Co., Ltd.'s valuation, stock price, and market status.

Is Suzhou HepaThera Biotech Co., Ltd. a public or private company?

Suzhou HepaThera Biotech Co., Ltd. is a private company.

What is the current stock price of Suzhou HepaThera Biotech Co., Ltd.?

Suzhou HepaThera Biotech Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.

How much is Suzhou HepaThera Biotech Co., Ltd. worth (valuation)?

Valuation information for Suzhou HepaThera Biotech Co., Ltd. is not publicly available.

Can I buy Suzhou HepaThera Biotech Co., Ltd. stock?

Suzhou HepaThera Biotech Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Suzhou HepaThera Biotech Co., Ltd.'s last funding round?

Suzhou HepaThera Biotech Co., Ltd.'s most recent funding round was Pre Seed on February 1, 2023.

Who are the main investors in Suzhou HepaThera Biotech Co., Ltd.?

Investor information for Suzhou HepaThera Biotech Co., Ltd. is not publicly disclosed.

Will Suzhou HepaThera Biotech Co., Ltd. IPO soon?

No public IPO plans have been announced for Suzhou HepaThera Biotech Co., Ltd..

How can I track Suzhou HepaThera Biotech Co., Ltd. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Suzhou HepaThera Biotech Co., Ltd.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Year Founded2021
Last FundingFeb 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?